Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:54 AM
Ignite Modification Date:
2025-12-25 @ 3:54 AM
NCT ID:
NCT01208402
Eligibility Criteria:
Inclusion Criteria:
1. Males or Females
2. Age \> 40y/o
3. Scheduled high risk (ASA II-IV) non-cardiac surgery with anticipated 12 hour post-operative ICU care
4. Written informed consent
5. Patients on a stable chronic oral beta-blocker therapy
6. Revised Cardiac Risk Index 1(below) Cardiac Risk Index 1 or greater (below)
* a history of coronary disease
* a history of congestive heart failure
* a history of treated diabetes
* a history of cerebrovascular disease
* a history of chronic renal failure
Exclusion Criteria:
1. Active bleeding
2. Untreated left main disease
3. Active cardiac condition (eg unstable angina pectoris, acute exacerbation of CHF, serious arrhythmias, symptomatic valve disease)
4. Preoperative positive troponin T
5. Contraindication for esmolol use
6. Previous allergy or intolerance to esmolol
7. Cancer with an expected life expectancy \< 6 months
8. Pregnancy or lactating or planning to become pregnant
9. Failure to provide informed consent, unable to understand or follow instructions.
10. History of drug allergy or idiosyncrasy to beta-adrenergic drugs
11. Recent history (within 1 year) of drug or alcohol abuse
12. Patients with a Pacemaker
13. Abnormal liver function Child-Pugh - B
14. Body Mass Index \> 45
15. Reactive airway disease (defined as a history of hospitalization with status asthmaticus within the past one year)
16. Surgery scheduled to begin after 2pm
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
41 Years
Study:
NCT01208402
Study Brief:
Protocol Section:
NCT01208402